Morvarid Karimi
Morvarid Karimi has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
Joel S. Perlmutter
Department of Neurology; Washington University School of Medicine; Saint Louis Missouri USA
3 shared publications- Joel S. Perlmutter
Department of Neurology, Washington University, St. Louis, Missouri, United States of America
3 shared publications - Brad A. Racette
Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA
2 shared publications - Daniel Truong
The Parkinson and Movement Disorder Institute, Fountain Valley, CA 92708, USA
2 shared publications - Mark Steven LeDoux
Veracity Neuroscience LLC, Memphis, Tennessee; University of Memphis, Memphis, Tennessee
2 shared publications - Peter Hedera
Department of Neurology, University of Louisville, Louisville, USA
2 shared publications
Latest Publications
- Open Access
- 10 December 2015
- Published by Springer Nature in EJNMMI Research
- Vol. 5 (1) , 1-6
Radiation dosimetry of [18F]VAT in nonhuman primates
The objective of this study is to determine the radiation dosimetry of a novel radiotracer for vesicular acetylcholine transporter (−)-(1-((2R,3R)-8-(2-[18F]fluoro-ethoxy)-3-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)piperidin-4-yl)(4-fluorophenyl)-methanone ([18F]VAT) based on PET imaging in nonhuman primates. [18F]VAT has potential for investigation of neurological disorders including Alzheimer’s disease, Parkinson’s disease, and dystonia. Three macaque fascicularis (two males, one female) received 185.4–198.3 MBq [18F]VAT prior to whole-body imaging in a MicroPET-F220 scanner. Time activity curves (TACs) were created from regions of interest (ROIs) that encompassed the entire small organs or samples with the highest activity within large organs. Organ residence times were calculated based on the TACs. We then used OLINDA/EXM 1.1 to calculate human radiation dose estimates based on scaled organ residence times. Measurements from directly sampled arterial blood yielded a residence time of 0.30 h in agreement with the residence time of 0.39 h calculated from a PET-generated time activity curve measured in the left ventricle. Organ dosimetry revealed the liver as the critical organ (51.1 and 65.4 μGy/MBq) and an effective dose of 16 and 19 μSv/MBq for male and female, respectively. The macaque biodistribution data showed high retention of [18F]VAT in the liver consistent with hepatobiliary clearance. These dosimetry data support that relatively safe doses of [18F]VAT can be administered to obtain imaging in humans.
- 10 December 2015
- Published by Springer Nature in EJNMMI Research
- Vol. 5 (1) , 1-6
Open AccessRadiation dosimetry of [18F]VAT in nonhuman primates
The objective of this study is to determine the radiation dosimetry of a novel radiotracer for vesicular acetylcholine transporter (−)-(1-((2R,3R)-8-(2-[18F]fluoro-ethoxy)-3-hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)piperidin-4-yl)(4-fluorophenyl)-methanone ([18F]VAT) based on PET imaging in nonhuman primates. [18F]VAT has potential for investigation of neurological disorders including Alzheimer’s disease, Parkinson’s disease, and dystonia. Three macaque fascicularis (two males, one female) received 185.4–198.3 MBq [18F]VAT prior to whole-body imaging in a MicroPET-F220 scanner. Time activity curves (TACs) were created from regions of interest (ROIs) that encompassed the entire small organs or samples with the highest activity within large organs. Organ residence times were calculated based on the TACs. We then used OLINDA/EXM 1.1 to calculate human radiation dose estimates based on scaled organ residence times. Measurements from directly sampled arterial blood yielded a residence time of 0.30 h in agreement with the residence time of 0.39 h calculated from a PET-generated time activity curve measured in the left ventricle. Organ dosimetry revealed the liver as the critical organ (51.1 and 65.4 μGy/MBq) and an effective dose of 16 and 19 μSv/MBq for male and female, respectively. The macaque biodistribution data showed high retention of [18F]VAT in the liver consistent with hepatobiliary clearance. These dosimetry data support that relatively safe doses of [18F]VAT can be administered to obtain imaging in humans.
- 21 October 2013
- Published by Wiley in Movement Disorders
- Vol. 28 (14) , 2002-2006
Striatal dopamine D1-like receptor binding is unchanged in primary focal dystonia
- 21 October 2013
- Published by Wiley in Movement Disorders
- Vol. 28 (14) , 2002-2006
Striatal dopamine D1-like receptor binding is unchanged in primary focal dystonia
- 19 October 2010
- Published by Wiley in Movement Disorders
- Vol. 26 (1) , 100-106
Decreased striatal dopamine receptor binding in primary focal dystonia: A D2 or D3 defect?
Dystonia is an involuntary movement disorder characterized by repetitive patterned or sustained muscle contractions causing twisting or abnormal postures. Several lines of evidence suggest that abnormalities of dopaminergic pathways contribute to the pathophysiology of dystonia. In particular, dysfunction of D2‐like receptors that mediate function of the indirect pathway in the basal ganglia may play a key role. We have demonstrated with positron emission tomography that patients with primary focal cranial or hand dystonia have reduced putamenal specific binding of [18F]spiperone, a nonselective D2‐like radioligand with nearly equal affinity for serotonergic 5‐HT(2A) sites. We then repeated the study with [18F]N‐methyl‐benperidol (NMB), a more selective D2‐like receptor radioligand with minimal affinity for 5‐HT(2A). Surprisingly, there was no decrease in NMB binding in the putamen of subjects with dystonia. Our findings excluded reductions of putamenal uptake greater than 20% with 95% confidence intervals. The analysis of the in vitro selectivity of NMB and spiperone demonstrated that NMB was highly selective for D2 receptors relative to D3 receptors (200‐fold difference in affinity), whereas spiperone has similar affinity for all three of the D2‐like receptor subtypes. These findings when coupled with other literature suggest that a defect in D3, rather than D2, receptor expression may be associated with primary focal dystonia. © 2010 Movement Disorder Society.
- 19 October 2010
- Published by Wiley in Movement Disorders
- Vol. 26 (1) , 100-106
Decreased striatal dopamine receptor binding in primary focal dystonia: A D2 or D3 defect?
Dystonia is an involuntary movement disorder characterized by repetitive patterned or sustained muscle contractions causing twisting or abnormal postures. Several lines of evidence suggest that abnormalities of dopaminergic pathways contribute to the pathophysiology of dystonia. In particular, dysfunction of D2‐like receptors that mediate function of the indirect pathway in the basal ganglia may play a key role. We have demonstrated with positron emission tomography that patients with primary focal cranial or hand dystonia have reduced putamenal specific binding of [18F]spiperone, a nonselective D2‐like radioligand with nearly equal affinity for serotonergic 5‐HT(2A) sites. We then repeated the study with [18F]N‐methyl‐benperidol (NMB), a more selective D2‐like receptor radioligand with minimal affinity for 5‐HT(2A). Surprisingly, there was no decrease in NMB binding in the putamen of subjects with dystonia. Our findings excluded reductions of putamenal uptake greater than 20% with 95% confidence intervals. The analysis of the in vitro selectivity of NMB and spiperone demonstrated that NMB was highly selective for D2 receptors relative to D3 receptors (200‐fold difference in affinity), whereas spiperone has similar affinity for all three of the D2‐like receptor subtypes. These findings when coupled with other literature suggest that a defect in D3, rather than D2, receptor expression may be associated with primary focal dystonia. © 2010 Movement Disorder Society.
- 1 April 2010
- Vol. 127 (4) , 470
Novel human pathological mutations. Gene symbol: THAP1. Disease: dystonia 6.
- 1 April 2010
- Vol. 127 (4) , 470
Novel human pathological mutations. Gene symbol: THAP1. Disease: dystonia 6.
- Open Access
- 11 March 2009
- Published by Springer Nature in BMC Medical Genetics
- Vol. 10 (1) , 24
High-throughput mutational analysis of TOR1A in primary dystonia
Although the c.904_906delGAG mutation in Exon 5 of TOR1A typically manifests as early-onset generalized dystonia, DYT1 dystonia is genetically and clinically heterogeneous. Recently, another Exon 5 mutation (c.863G>A) has been associated with early-onset generalized dystonia and some ΔGAG mutation carriers present with late-onset focal dystonia. The aim of this study was to identify TOR1A Exon 5 mutations in a large cohort of subjects with mainly non-generalized primary dystonia.
- 11 March 2009
- Published by Springer Nature in BMC Medical Genetics
- Vol. 10 (1) , 24
Open AccessHigh-throughput mutational analysis of TOR1A in primary dystonia
Although the c.904_906delGAG mutation in Exon 5 of TOR1A typically manifests as early-onset generalized dystonia, DYT1 dystonia is genetically and clinically heterogeneous. Recently, another Exon 5 mutation (c.863G>A) has been associated with early-onset generalized dystonia and some ΔGAG mutation carriers present with late-onset focal dystonia. The aim of this study was to identify TOR1A Exon 5 mutations in a large cohort of subjects with mainly non-generalized primary dystonia.